Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
324.93
-0.24 (-0.07%)
Sep 3, 2026, 2:12 PM EDT - Market open
Natera Revenue
Natera had revenue of $752.75M in the quarter ending June 30, 2026, with 37.71% growth. This brings the company's revenue in the last twelve months to $2.71B, up 37.82% year-over-year. In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth.
Revenue (ttm)
$2.71B
Revenue Growth
+37.82%
P/S Ratio
17.31
Revenue / Employee
$440,892
Employees
6,140
Market Cap
46.84B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
| Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
| Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
| Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
| Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
| Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
| Dec 31, 2013 | 55.17M | 40.92M | 287.16% |
| Dec 31, 2012 | 14.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Danaher | 25.11B |
| IQVIA Holdings | 16.98B |
| Labcorp Holdings | 14.35B |
| Quest Diagnostics | 11.56B |
| Agilent Technologies | 7.37B |
| Waters | 4.64B |
| IDEXX Laboratories | 4.55B |
| Illumina | 4.49B |
NTRA News
- 1 day ago - Why Moderna's Cancer Vaccine Matters to Investors - ETF Trends
- 2 days ago - Natera announces publication of new data in Blood Neoplasia on Signatera - TheFly
- 2 days ago - New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma - Business Wire
- 6 days ago - Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer - Business Wire
- 7 days ago - Natera and Angiex partner in tumor testing using Signatera - TheFly
- 7 days ago - Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ - Business Wire
- 17 days ago - Natera to support new clinical trial assessing ctDNA dynamics with Latitude - TheFly
- 17 days ago - Natera price target raised to $363.50 from $249 at Piper Sandler - TheFly